Recently, some trials have shown that patients with type 2 diabetes mellitus who received an inhibitor of sodium-glucose cotransporter 2 in addition to conventional therapy had significantly lower rates of cardiovascular morbidity and mortality than did patients with type 2 diabetes mellitus who received a placebo in addition to conventional therapy32–34. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.